GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing King-Friend Biochemical Pharmaceutical Co Ltd (SHSE:603707) » Definitions » EV-to-FCF

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) EV-to-FCF : 17.51 (As of May. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nanjing King-Friend Biochemical Pharmaceutical Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nanjing King-Friend Biochemical Pharmaceutical Co's Enterprise Value is ¥22,213 Mil. Nanjing King-Friend Biochemical Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,269 Mil. Therefore, Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-FCF for today is 17.51.

The historical rank and industry rank for Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-FCF or its related term are showing as below:

SHSE:603707' s EV-to-FCF Range Over the Past 10 Years
Min: -757.71   Med: -33.82   Max: 270.61
Current: 17.51

During the past 11 years, the highest EV-to-FCF of Nanjing King-Friend Biochemical Pharmaceutical Co was 270.61. The lowest was -757.71. And the median was -33.82.

SHSE:603707's EV-to-FCF is ranked better than
59.81% of 525 companies
in the Drug Manufacturers industry
Industry Median: 24.52 vs SHSE:603707: 17.51

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Nanjing King-Friend Biochemical Pharmaceutical Co's stock price is ¥13.39. Nanjing King-Friend Biochemical Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-0.220. Therefore, Nanjing King-Friend Biochemical Pharmaceutical Co's PE Ratio for today is At Loss.


Nanjing King-Friend Biochemical Pharmaceutical Co EV-to-FCF Historical Data

The historical data trend for Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing King-Friend Biochemical Pharmaceutical Co EV-to-FCF Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.18 -40.41 219.80 245.22 20.79

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 196.17 52.27 25.78 20.79 14.73

Competitive Comparison of Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-FCF falls into.



Nanjing King-Friend Biochemical Pharmaceutical Co EV-to-FCF Calculation

Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=22213.200/1268.522
=17.51

Nanjing King-Friend Biochemical Pharmaceutical Co's current Enterprise Value is ¥22,213 Mil.
Nanjing King-Friend Biochemical Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,269 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanjing King-Friend Biochemical Pharmaceutical Co  (SHSE:603707) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nanjing King-Friend Biochemical Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.39/-0.220
=At Loss

Nanjing King-Friend Biochemical Pharmaceutical Co's share price for today is ¥13.39.
Nanjing King-Friend Biochemical Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.220.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Nanjing King-Friend Biochemical Pharmaceutical Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Nanjing King-Friend Biochemical Pharmaceutical Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Business Description

Traded in Other Exchanges
N/A
Address
1/16 Xuefu Road, Nanjing High-Tech Zone, Nanjing, CHN, 210061
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
Executives
Huang Xi Wei Director
Liu Zu Qing Supervisors
Xie Ju Hua Director
Wu Gui Ping senior management
Tang Yong Qun Director
Qian Xiao Jie senior management

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Headlines

No Headlines